TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12795643
Drug: Insulin‐standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin‐standard treatment (ST)
Study: 8933299
Drug: Face-to-face prescribing
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face prescribing discussion visits led by a pharmaceutical prescribing adviser (Group 1)
Study: 8456595
Drug: Oxiracetam (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiracetam (1600 mg/day)
Study: 3873511
Drug: Ten-day trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten-day trimethoprim-sulfamethoxazole treatment
Study: 30022331
Drug: Bilateral Dysport®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral Dysport® injections (50+50 units)
Study: 30022331
Drug: Unilateral Dysport®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral Dysport® injections (100 units)
Study: 21254871
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg of ethinyl estradiol (EE)/3 mg of drospirenone (DRSP) plus 100 mg of cyproterone acetate (CPA)
Study: 21254871
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg of EE/3 mg of DRSP plus 100 mg of spironolactone
Study: 21254871
Drug: 35 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 μg of EE/2 mg of CPA plus 100 mg of CPA
Study: 18727456
Drug: L‐methionine‐1‐13COOH
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐methionine‐1‐13COOH
Study: 10944138
Drug: Reinduction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinduction therapy before DLI
Study: 8839865
Drug: VBMCP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: VBMCP treatment
Study: 8839865
Drug: VBMCP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: VBMCP + alternating high doses of cyclophosphamide + prednisone
Study: 1592959
Drug: No-pill condition
Normalized name: No Doz Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-pill condition
Study: 30621562
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab treatment plus ZQMT
Study: 30621562
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab treatment alone
Study: 11423507
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone (RSG) 8 mg daily
Study: 11423507
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone (RSG) 4 mg daily
Study: 3314750
Drug: Graded-sequential filling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graded-sequential filling
Study: 2694799
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg of Madopar HBS
Study: 25432773
Drug: Odanacatib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib (50 mg once weekly)
Study: 16690557
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum tablets
Study: 9260215
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with house dust mite extract (D.pt.)
Study: 29412458
Drug: Oliceridine (TRV130)
Normalized name: Oliceridine
DrugBank: Oliceridine (DB14881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oliceridine (TRV130) administered in doses ranging from 0.5 to 4 mg every 3-4 hours during the phase 2 study.
Study: 29412458
Drug: Oliceridine (TRV130)
Normalized name: Oliceridine
DrugBank: Oliceridine (DB14881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oliceridine (TRV130) administered in single doses ranging from 0.15 to 7 mg and multiple doses ranging from 0.4 to 4.5 mg every 4-6 hours during the phase 1 study.
Study: 27074824
Drug: Finerenone (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone (2.5, 5, 7.5, 10 or 15 mg, up-titrated to 5, 10, 15, 20, or 20 mg, respectively, on day 30)
Study: 27074824
Drug: Eplerenone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (25 mg every other day, increased to 25 mg o.d. on day 30, and 50 mg on day 60)
Study: 20826243
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading dose followed by 75 mg/d) + Aspirin (75 mg/d for first 21 days)
Study: 20826243
Drug: Aspirin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (75 mg/d) alone
Study: 19030110
Drug: Absolute Risk
Normalized name: Honey Absolute
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absolute Risk Reduction, Number Needed to Treat, Event Rates, Tablets Needed to Take, Natural Frequencies
Study: 12815479
Drug: Control (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (high-dose therapy only)
Study: 29338824
Drug: Isokinetic eccentric
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isokinetic eccentric training with whey protein isolate supplement (IE + WPI)
Study: 23601460
Drug: Tobramycin dexamethasone
Normalized name: dexamethasone / tobramycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin dexamethasone eye ointment
Study: 23601460
Drug: Tobramycin eye
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin eye ointment (Control)
Study: 12735660
Drug: Cumulative dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative dose regimen of formoterol (9 + 9 + 18 microg, total 36 microg)
Study: 12735660
Drug: Single high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high dose of formoterol (36 microg)
Study: 12735660
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment regimens (cumulative and single high dose)
Study: 10620003
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (EPA 3.2 g, DHA 2.4 g)
Study: 8841150
Drug: Arecoline (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arecoline (4 mg/day, n = 6)
Study: 8841150
Drug: Arecoline (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arecoline (16 mg/day, n = 3)
Study: 8841150
Drug: Arecoline (optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arecoline (optimal dose for memory enhancement)
Study: 8841150
Drug: Arecoline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arecoline (0.5 to 40 mg/day during multiple-dose infusions)
Study: 6435644
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate spray (2 sprays, 2.5 mg)
Study: 6435644
Drug: Sublingual glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual glyceryl trinitrate (0.3 mg)
Study: 6435644
Drug: Ordinary isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary isosorbide dinitrate tablet (5 mg)
Study: 30895698
Drug: Narrow diameter
Normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow diameter implants (NDIs) (< 3.3 mm)
Study: 30895698
Drug: Regular diameter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular diameter implants (RDIs) (4.1 mm)
Study: 30895698
Drug: Narrow diameter
Normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow diameter implants (NDIs) and Regular diameter implants (RDIs)
Study: 17123696
Drug: PCOS patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCOS patients without insulin resistance
Study: 9144613
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol based bisacodyl suppository (PEGBS)
Study: 9144613
Drug: Conventional bisacodyl
Normalized name: Bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional bisacodyl suppository based in hydrogenated vegetable oil (HVOBS)
Study: 7011349
Drug: aminophylline (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: aminophylline (0.2 mg kg‐1 min‐1 for 30 min)
Study: 30144242
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (antimycotic or steroid) and probiotic
Study: 25438680
Drug: Thiamylal (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamylal (1.5 mg/kg)
Study: 22909145
Drug: EE 0.03 mg/drospirenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE 0.03 mg/drospirenone 3 mg/levomefolate calcium 0.451 mg (SAFYRAL®)
Study: 22909145
Drug: EE 0.03 mg/drospirenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE 0.03 mg/drospirenone 3 mg (Yasmin®)
Study: 22909145
Drug: levomefolate calcium
Normalized name: Levomefolate Calcium
DrugBank: Levomefolic acid (DB11256)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: levomefolate calcium 0.451 mg
Study: 16230721
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin plus oral agents (n = 103)
Study: 16230721
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin alone (n = 104)
Study: 16230721
Drug: Oral agent
Normalized name: DENTAL AND ORAL AGENTS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral agent therapy alone (n = 99)
Study: 12173326
Drug: Estramustine phosphate
Normalized name: Estramustine phosphate
DrugBank: Estramustine phosphate (DB14674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estramustine phosphate (EMP) as first-line therapy
Study: 7781349
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (2 g IV)
Study: 7781349
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (2 g IV) in severe group
Study: 7781349
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (2 g IV) in moderate group
Study: 2278325
Drug: Continuous interpleural
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous interpleural analgesia with 20 ml bupivacaine 0.5% with adrenaline 5 micrograms/ml
Study: 2278325
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of interpleural bupivacaine and systemic morphine
Study: 31702761
Drug: Cranberry +health™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry +health™ cranberry supplement (cranberry chew)
Study: 29090491
Drug: MRI Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI Group (MG) - Accent MRI™ conditional pacing system, n = 140
Study: 26044566
Drug: cilostazol 200
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cilostazol 200 mg/day
Study: 21692286
Drug: Meridian‐collateral electric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meridian‐collateral electric information therapy combined with pricking and cupping
Study: 21692286
Drug: Acyclovir administered
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir administered orally
Study: 19747869
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group maintained usual daily activity
Study: 14750569
Drug: Intracameral or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracameral or intravitreal injection of 0.1 mL antibiotic (40 microg gentamicin and 45 microg clindamycin)
Study: 14750569
Drug: Balanced saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced saline solution (BSS) injection
Study: 9662313
Drug: Daily placement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily placement of prostaglandin gel
Study: 9662313
Drug: Daily membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily membrane stripping
Study: 9662313
Drug: Daily cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily cervical examinations
Study: 10208998
Drug: Lovastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (40 mg/d) and colestipol (30 g/d)
Study: 10208998
Drug: Niacin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin (4 g/d) and colestipol
Study: 10208998
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with placebo alone or with colestipol
Study: 2142911
Drug: Picotamide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picotamide (600 mg daily for six months)
Study: 24374394
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic solution (LAS) applied to the columella (2 mL of 2% prilocaine with 1:80,000 adrenaline)
Study: 24374394
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic solution (LAS) applied to the nasal dorsum (2 mL of 2% prilocaine with 1:80,000 adrenaline)
Study: 24374394
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic solution (LAS) applied to the nasal dorsum followed by LAS to the columella after 10 minutes (2 mL of 2% prilocaine with 1:80,000 adrenaline)
Study: 17086465
Drug: 4:00 PM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4:00 PM inhalation of 4.5% saline
Study: 17086465
Drug: 4:00 AM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4:00 AM inhalation of 4.5% saline
Study: 15583260
Drug: Safe storage
Normalized name: Safe-Guard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safe storage of medicines
Study: 11704585
Drug: Turbuhaler (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turbuhaler (0.25 mg terbutaline)
Study: 11704585
Drug: Turbuhaler (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turbuhaler (0.5 mg terbutaline)
Study: 11704585
Drug: pMDI (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: pMDI (0.25 mg terbutaline)
Study: 11704585
Drug: pMDI (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: pMDI (0.5 mg terbutaline)
Study: 2917596
Drug: 5-Methoxypsoralen (5-MOP)
Normalized name: 5 methoxypsoralen
DrugBank: Bergapten (DB12216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Methoxypsoralen (5-MOP) 40 mg/day
Study: 31696603
Drug: Mid-dose (PHEN/TPM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-dose (PHEN/TPM 7.5 mg/46 mg)
Study: 31696603
Drug: Top-dose (PHEN/TPM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Top-dose (PHEN/TPM 15 mg/92 mg)
Study: 31696603
Drug: Mid-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-dose
Study: 31696603
Drug: Top-dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Top-dose
Study: 18379058
Drug: Patch adhesion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch adhesion
Study: 16441467
Drug: 1-week triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week triple therapy for eradication of H. pylori
Study: 16441467
Drug: Crossover open-label
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover open-label triple therapy
Study: 12969090
Drug: HM-CAP (immunoglobulin-G)
Normalized name: DEXTRAN HM
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM-CAP (immunoglobulin-G)
Study: 12969090
Drug: Pyloriset EIA-G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyloriset EIA-G
Study: 10710743
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist leuprolide acetate, 3.75 mg intramuscularly every 28 days
Study: 3903644
Drug: Metoclopramide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (1 mg/kg, intravenous)
Study: 3903644
Drug: Bethanechol (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bethanechol (0.075 mg/kg, subcutaneous)
Study: 29066028
Drug: Group B2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B2: 80 kVp, 30 ml of iohexol at 4.5 ml/s; hybrid iterative reconstruction (HIR) and IMR.
Study: 29066028
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 120 kVp, 50 ml of iopromide at a flow rate of 5 ml/s; filtered back projection (FBP) reconstruction.
Study: 24041792
Drug: ITX5061 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITX5061 150 mg/day for 28 days (C150)
Study: 24041792
Drug: ITX5061 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITX5061 150 mg/day for 3 days (A150)
Study: 24041792
Drug: ITX5061 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITX5061 150 mg/day for 14 days (B150)
Study: 22705785
Drug: Lactobacillus acidophilus
Normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus acidophilus strain L-55-contained yogurt
Study: 19558057
Drug: 5000 IU
Normalized name: D 5000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 IU of intravenous heparin during surgery
Study: 12399203
Drug: H-B-VAXII (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-B-VAXII (0.5 ml, 5 micro g HBsAg) intramuscular injection at birth, 1, and 6 months (Schedule A)
Study: 12399203
Drug: H-B-VAXII (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-B-VAXII (0.5 ml, 5 micro g HBsAg) intramuscular injection at birth, 1, 2, and 12 months (Schedule B)
Study: 1775523
Drug: Prazepam (30‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazepam (30‐60 mg)
Study: 1775523
Drug: Clomipramine (75‐150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (75‐150 mg)
Study: 31804659
Drug: Standard multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard multimodal treatment
Study: 27595142
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg intravenous infusion given over 2 h at baseline, and again at 2 weeks and 6 weeks after the first infusion)
Study: 27595142
Drug: Ciclosporin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin (2 mg/kg per day by continuous infusion for up to 7 days, followed by twice-daily tablets delivering 5.5 mg/kg per day for 12 weeks)
Study: 17301634
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) with endurance training (ET)
Study: 17301634
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) without endurance training (ET)
Study: 9879918
Drug: Intensive fluoride
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive fluoride mouthrinsing (10 ml of 0.045% NaF neutral solution once a day for 3 days, twice a year, totaling 6 rinses per year)
Study: 2525449
Drug: Clinofibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinofibrate (200 mg, three times daily for 16 weeks)
Study: 2525449
Drug: Placebo (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (200 mg, three times daily for 16 weeks)
Study: 29753264
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg dexamethasone)
Study: 25795409
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus gemcitabine (cisplatin 75 mg/m² on day 1 and gemcitabine 1250 mg/m² on days 1 and 8)
Study: 25795409
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus gemcitabine (paclitaxel 175 mg/m² on day 1 and gemcitabine 1250 mg/m² on days 1 and 8)
Study: 20649689
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg/d with or without medroxyprogesterone acetate (MPA, 10 mg/d)
Study: 20649689
Drug: CEE alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE alone therapy
Study: 15363253
Drug: Portal vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Portal vein chemotherapy (5‐fluorouracil infusion at 1g per day for 7 days after operation)
Study: 15363253
Drug: Intraluminal chemotherapy
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraluminal chemotherapy (5‐fluorouracil 0.5 g injected during operation)
Study: 11215556
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplementation (Group 1)
Study: 9024252
Drug: Recombinant GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant GH treatment for 9 months (adjusted for body surface area) in men
Study: 9024252
Drug: Recombinant GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant GH treatment for 9 months (adjusted for body surface area) in women
Study: 9024252
Drug: Recombinant GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant GH treatment for 9 months in men
Study: 8274360
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium supplementation (366 mg Mg2+/d)
Study: 3095501
Drug: Chex‐UP chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chex‐UP chemotherapy (four-drug combination: cyclophosphamide, hexamethylmelamine, 5‐fluorouracil, and cisplatin)
Study: 3095501
Drug: Chex‐UP chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chex‐UP chemotherapy
Study: 15890758
Drug: Moderate doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate doses of training (3-6 months)
Study: 15890758
Drug: Heavy doses
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy doses of training (12 months)
Study: 8798349
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Daflon 500 mg with LMWH (Group B: n = 595)
Study: 8798349
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Daflon 500 mg with LMWH (Group D: n = 93)
Study: 29663871
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (15 mg for men; 12 mg for women)
Study: 27906432
Drug: Concurrent radio
Normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent radio chemotherapy and intensity modulated radiotherapy